Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters
Abstract Aims To evaluate echocardiographic and biomarker changes during chemotherapy, assess their ability to early detect and predict cardiotoxicity and to define the best time for their evaluation. Methods and results Seventy‐two women with breast cancer (52 ± 9.8 years) treated with anthracyclin...
Main Authors: | Belén Díaz‐Antón, Rodrigo Madurga, Blanca Zorita, Samantha Wasniewski, Andrea Moreno‐Arciniegas, Beatriz López‐Melgar, Natalia Ramírez Merino, Roberto Martín‐Asenjo, Patricia Barrio, Maximiliano German Amado Escañuela, Jorge Solís, Francisco Javier Parra Jiménez, Eva Ciruelos, José María Castellano, Leticia Fernández‐Friera |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-04-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.13782 |
Similar Items
-
Cardiotoxicity: Importance of biomarkers
by: Kostadinović Jelena, et al.
Published: (2023-01-01) -
Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01) -
Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study
by: Husam Abdel‐Qadir, et al.
Published: (2021-01-01) -
Is Electrocardiogram Helpful in Predicting a Rise in Troponin I as a Marker of Anthracycline Cardiotoxicity?
by: Kader Muneer, et al.
Published: (2022-10-01) -
Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01)